Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
Pliant Therapeutics, Inc. (PLRX)
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, announced its presentations at the European Respiratory Society (ERS) International Congress 2024 taking place in Vienna, Austria September 7 - 11, 2024. “Presentations made by Pliant colleagues and investigators at the 2024 ERS Congress include additional clinical data from our recently announced type 1 collagen PET imaging study, an integrated safety summary from our INTEGRIS clinical programs and non-clinical data from our bexotegrast development program. Taken together, these data provide further support for the late-stage development of this novel therapeutic as part of our ongoing BEACON-IPF trial,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics. Bexotegrast reduces type 1 collagen deposition in parti
Show less
Read more
Impact Snapshot
Event Time:
PLRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLRX alerts
High impacting Pliant Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PLRX
News
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.MarketBeat
- PF Awareness Month emphasises the importance of early diagnosis [Yahoo! Finance]Yahoo! Finance
- Pliant Therapeutics: Good Data, But Will Need Watching [Seeking Alpha]Seeking Alpha
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Pliant Therapeutics, Inc. (NASDAQ: PLRX) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $33.00 price target on the stock.MarketBeat
PLRX
Earnings
- 11/9/23 - Beat
PLRX
Sec Filings
- 9/27/24 - Form 8-K
- 8/7/24 - Form 10-Q
- 8/7/24 - Form 8-K
- PLRX's page on the SEC website